NLS Pharma has just announced new data which further supports the mechanism of action of Mazindol. Mazindol is the active ingredient in Quilience, a treatment used for narcolepsy. This therapy…
The 34th Annual Meeting of the Associated Professional Sleep Societies, or "SLEEP 2020," was held last week from August 27th through the 30th. According to BioSpace, pharmaceutical company Harmony Biosciences…
According to a story from Sleep Review, the drug company Jazz Pharmaceuticals plc has recently filed a New Drug Application (NDA) for its investigational treatment JZP-258, which is being developed…
This is part two of the story, click here to read part one After searching for a new neurologist, we found one only 30 mins away that was willing…
I want to start off by saying that the intention behind my words are not to convey or express any sort of anger, hatred, or resentment. I am choosing to…
According to a story from Biotech 365, the biopharmaceutical company Avadel Pharmaceuticals plc recently announced that it has completed enrollment for its phase 3 clinical trial. This trial will test…
Narcolepsy is characterized by drowsiness, often during the daytime. This is a symptom that greatly affects the lives of those with narcolepsy, and for a long time no FDA…
Narcolepsy is a rare neurological disease that affects the sleep cycle. Symptoms include sleep paralysis, excessive daytime sleepiness, disrupted nighttime sleep, hypnagogic hallucinations, and, for around 70% of patients, cataplexy.…
According to a story from PR Newswire, the biopharmaceutical company Harmony Biosciences, LLC recently announced that the US Food and Drug Administration (FDA) has approved the company's drug pitolisant (marketed…
According to a story from Neuroscience News, a team of researchers based out of the University of Copenhagen have made an intriguing discovery that could give new insight into the…
Narcolepsy and Cataplexy Narcolepsy is a neurological condition that results in a malfunctioning sleep-wake cycle. It affects approximately 185,000 individuals in the United States alone. Some of the most common…
The FDA has approved a new narcolepsy and cataplexy treatment for pediatric patients! Xyrem is a drug used to control narcolepsy symptoms including cataplexy and excessive daytime sleepiness (EDS). It…
A new study explored the mechanisms underlying narcolepsy, a rare sleep disorder. The condition has previously been linked to reduced levels of a neurotransmitter called hypocretin, and the recent study…
According to a story from kait8.com, the company Harmony Biosciences, Inc., has recently announced that the U.S. FDA has given Fast Track and Breakthrough Therapy designations for its experimental therapy…
A new study looking at a test used to diagnose narcolepsy has found that it often produces inconsistent results for the same patients, reports Sleep Review. This highlights a current…
According to an article from FinancialBuzz, the pharmaceutical company Avadel announced that its product FT 218 has been granted orphan drug status by the Food and Drug Administration (FDA) as…
Baby Dylan had some sort of medical condition, as reported by The Global and Mail. His family was sure of it. He slept all the time and when he was…
The Associated Professional Sleep Societies held their 31st annual meeting in Boston June 3rd through 7th. You can read more about Sleep 2017 by clicking here. Among other discussions was cataplexy.…
At a recent conference, Jazz Pharmaceuticals presented positive efficacy results from the JZP-110 (TONES) studies in adult patients with sleep impairment conditions and the excessive sleepiness associated with these diseases.…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
